Corien Eeltink1,2, Alaa Embaby3, Luca Incrocci4, Johannes C F Ket5, Sarah J Liptrott6,7, Irma Verdonck-de Leeuw8, Sonja Zweegman9,10. 1. Cancer Center Amsterdam (CCA), Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. C.Eeltink@amsterdamumc.nl. 2. Department of Hematology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. C.Eeltink@amsterdamumc.nl. 3. Department of Clinical Pharmacology, Netherlands Cancer Institute, Antoni van Leeuwenhoekziekenhuis, Amsterdam, The Netherlands. 4. Department of Radiotherapy-Oncology/Sexology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 5. Medical Library, Vrije Universiteit, Amsterdam, The Netherlands. 6. IEO, European Institute of Oncology IRCCS, Milan, Italy. 7. Ente Ospedaliero Cantonale, via Gallino 12, 6500, Bellinzona, Switzerland. 8. Department of Otolaryngology-Head and Neck Surgery, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 9. Cancer Center Amsterdam (CCA), Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. 10. Department of Hematology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
PURPOSE: Sexual problems are frequently reported by recipients of hematopoietic stem cell transplantation (HCT). However, little is known about the impact of hematological malignancies and their treatments, without HCT being a part of the treatment regimen. The goal of this systematic review was to examine the prevalence of various sexual problems among patients treated for hematological malignancies without HCT. METHODS: The work focused on online databases available from their inception until 11 November 2020. The data related to sexuality in adult patients diagnosed with hematological malignancies. Selected studies were appraised for methodological quality. RESULTS: Twenty-four studies were included. Twenty-two studies were observational cross-sectional cohort studies, and two studies had a prospective longitudinal design; fourteen studies used non-validated instruments; only two studies used the multidimensional concept of sexuality; six studies compared sexual problems in the target population with reference data. Based on the few high-quality studies, sexual problems occurred in 18-50% of acute leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma patients. CONCLUSION: Understanding sexual problems in patients treated for hematological malignancies without HCT is not only hampered by the variability in methodology, but also by the lack of research on patients using novel therapies. The exact impact of the diagnosis and treatment of a hematological malignancy on sexual function remains to be answered. Longitudinal studies focusing on the effects of the diagnosis and treatment of hematological malignancies on sexuality using validated questionnaires and comparison with normative data are hugely needed.
PURPOSE: Sexual problems are frequently reported by recipients of hematopoietic stem cell transplantation (HCT). However, little is known about the impact of hematological malignancies and their treatments, without HCT being a part of the treatment regimen. The goal of this systematic review was to examine the prevalence of various sexual problems among patients treated for hematological malignancies without HCT. METHODS: The work focused on online databases available from their inception until 11 November 2020. The data related to sexuality in adult patients diagnosed with hematological malignancies. Selected studies were appraised for methodological quality. RESULTS: Twenty-four studies were included. Twenty-two studies were observational cross-sectional cohort studies, and two studies had a prospective longitudinal design; fourteen studies used non-validated instruments; only two studies used the multidimensional concept of sexuality; six studies compared sexual problems in the target population with reference data. Based on the few high-quality studies, sexual problems occurred in 18-50% of acute leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma patients. CONCLUSION: Understanding sexual problems in patients treated for hematological malignancies without HCT is not only hampered by the variability in methodology, but also by the lack of research on patients using novel therapies. The exact impact of the diagnosis and treatment of a hematological malignancy on sexual function remains to be answered. Longitudinal studies focusing on the effects of the diagnosis and treatment of hematological malignancies on sexuality using validated questionnaires and comparison with normative data are hugely needed.
Authors: R E Nappi; L Cucinella; E Martini; M Rossi; L Tiranini; S Martella; D Bosoni; C Cassani Journal: Climacteric Date: 2019-03-22 Impact factor: 3.005
Authors: Lisa B Kenney; Zoltan Antal; Jill P Ginsberg; Bradford S Hoppe; Sharon L Bober; Richard N Yu; Louis S Constine; Hanneke M van Santen; Roderick Skinner; Daniel M Green Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Richard Sadovsky; Rosemary Basson; Michael Krychman; Antonio Martin Morales; Leslie Schover; Run Wang; Luca Incrocci Journal: J Sex Med Date: 2010-01 Impact factor: 3.802
Authors: Milena Sant; Pamela Minicozzi; Morgane Mounier; Lesley A Anderson; Hermann Brenner; Bernd Holleczek; Rafael Marcos-Gragera; Marc Maynadié; Alain Monnereau; Gemma Osca-Gelis; Otto Visser; Roberta De Angelis Journal: Lancet Oncol Date: 2014-07-13 Impact factor: 41.316